Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) announced today that the clinical data for an investigational inhibitor of cyclin-dependent kinase 9 (CDK9), alvocidib (generic name), will be presented in an oral session at the American Society of Hematology(ASH) Annual Meeting and Exposition in San Diego from December 1 to 4, 2018.
For your information, the clinical data to be presented at the oral session are the stage-1 results of a phase 2 study, Zella 201, for alvocidib in patients with relapsed or refractory MCL-1- dependent Acute Myeloid Leukemia (NCT02520011).
The abstract is now available on the official website of ASH. (https://ash.confex.com/ash/2018/webprogram/start.html)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.